Grant Award Details
To develop an inhibitory monoclonal antibody (mAb) therapeutic against Tspan3 for treating AML.
Grant Application Details
- Targeting Cancer Stem Cells in Hematologic Malignancies
We will develop a biotherapeutic/monoclonal antibody that blocks the growth of human AML cancer stem cells in vitro and in vivo.
Treatment of the cancer stem cell driven disease Acute Myelogenous Leukemia (AML) will be impacted. AML is the most common acute leukemia in adults and current treatments are largely ineffective.
Major Proposed Activities
- Development of monoclonal antibodies
- Identification of monoclonal antibodies that can block human AML growth in vitro
- Optimization of dose and delivery of monoclonal antibodies in vivo
- Identification of monoclonal antibodies that can block human AML growth in vivo
- Define impact of monoclonal antibodies on cancer stem cells in vivo by high resolution imaging
Because this research will lead to the development of new treatments for the deadly disease acute myelogenous leukemia, the State of California and its citizens will directly benefit. While AML is the most common adult leukemia, it also accounts for more than 50% of all leukemia-associated mortality in children. Thus, if successful, the biotherapeutic we propose to develop would improve outcomes for patients across a broad range of ages throughout the State of California